![PRD_000186 PRD_000186](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_000186.svg) | PRD_000186 | Name: | EFRAPEPTIN C | Formula: | C80 H138 N18 O16 | Description: | EFRAPEPTIN C IS A LINEAR PEPTIDE, WITH ACETYLATED
(ACE) PIPECOLIC ACID (YCP) AT THE N-TERMINUS AND
A MODIFIED LEUCINE AT THE C-TERM (TLX) | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_000403 PRD_000403](https://data.pdbj.org/pdbjplus/data/cc/svg/1ZK.svg) | PRD_000403 | Name: | 4-[(2R)-3-{[(1S,2S,3R,4S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methyl-4-({(1S,2R)-2-methyl-1-[(pyridin-2-ylmethyl)carba
moyl]butyl}carbamoyl)hexyl]amino}-2-{[(naphthalen-1-yloxy)acetyl]amino}-3-oxopropyl]-1H-imidazol-3-ium | Formula: | C45 H62 N7 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
![PRD_002431 PRD_002431](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_002431.svg) | PRD_002431 | Name: | Cyclic tetraadenosine monophosphate (cA4) | Formula: | C40 H48 N20 O24 P4 | Description: | Cyclic oligoadenylates such as c-tetraAMP were found to be novel bacterial second messengers. Antiviral in context of signalling for Type III CRISPR-Cas systems. | Definition date: | 2023-07-12 | Last modified: | 2023-07-03 |
|
![PRD_001109 PRD_001109](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001109.svg) | PRD_001109 | Name: | peptide ligand | Formula: | C35 H51 Cl N6 O10 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|
![PRD_001111 PRD_001111](https://data.pdbj.org/pdbjplus/data/prd/svg/PRD_001111.svg) | PRD_001111 | Name: | peptide ligand | Formula: | C35 H50 Cl2 N6 O10 | Definition date: | 2012-12-12 | Last modified: | 2013-06-03 |
|